Clinical Trials Logo

Filter by:
NCT ID: NCT06394622 Recruiting - Solid Tumor Clinical Trials

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors

Start date: April 11, 2024
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC729 in the treatment of advanced malignant solid tumors. Condition or disease:advanced malignant solid tumors. Intervention/treatment:Biological: CD70 CAR-NKT cells. Phase:I

NCT ID: NCT06408350 Recruiting - HIV Clinical Trials

Optimal Intervention to Full Viral Suppression: Text Me, Alexis!

Start date: April 11, 2024
Phase: N/A
Study type: Interventional

Text Me, Alexis! is a three-arm randomized controlled trial (RCT) to determine the optimal and most cost-effective intervention for advancing trans women living with HIV to full viral suppression. Participants will be randomized (1:1:1) to Peer Health Navigation (PHN) alone, SMS (text messaging) alone, or PHN+SMS. Participants in the PHN alone and PHN+SMS arms will receive unlimited navigation sessions over 3 months. Participants in the SMS alone and PHN+SMS arms will receive 3 daily theory-based text messages for 90 days for a total of 270 unique scripted messages.

NCT ID: NCT06411405 Recruiting - Neonatal Sepsis Clinical Trials

Using Machine Learning to Model Early-onset Neonatal Sepsis Risk in Uganda and Zimbabwe

NeoRisk
Start date: April 11, 2024
Phase:
Study type: Observational

The goal of this observational study is to develop a risk prediction model for early-onset neonatal sepsis in term and late preterm neonates in Uganda and Zimbabwe. The main questions it aims to answer are: - What are the risk factors for early-onset neonatal sepsis in low-resource settings? - How can these be combined into a risk prediction model? Mother-baby pairs will be recruited in Uganda. They will have extensive data taken on their medical and obstetric histories and lifestyles, and their newborns will have a blood sample taken just after birth for culture. Machine learning techniques will be used to create the risk prediction model, which will then be validated in a second population in Zimbabwe.

NCT ID: NCT06456151 Recruiting - Clinical trials for Invasive Candidiasis

Invasive Candidiasis in Critical Care

Start date: April 11, 2024
Phase:
Study type: Observational

The combination of acute phase marker monitoring and the "T2Candida" assay (name of the test) will represent an acceleration of the identification of the causative agent of mycotic infection, a significant improvement in the specificity and positive predictive value of this strategy in the diagnosis of invasive candidiasis and candidemia in ICU patients, thereby improving the clinical condition of patients and reducing the cost of specific antifungal therapy.

NCT ID: NCT02754297 Recruiting - Clinical trials for Neuroendocrine Tumors

Personalized PRRT of Neuroendocrine Tumors

P-PRRT
Start date: April 12, 2016
Phase: Phase 2
Study type: Interventional

In this study, peptide receptor radionuclide therapy (PRRT) with 177Lu-Octreotate (LuTate) will be personalized, i.e. administered activity of LuTate will be tailored for each patient to maximize absorbed radiation dose to tumor, while limiting that to healthy organs. The purpose of this study is to: - Assess the objective (radiological), symptomatic and biochemical response rates following an induction course of personalized PRRT; - Assess the overall, the disease-specific, and the progression-free survival following P-PRRT; - Correlate therapeutic response and survival with tumor absorbed radiation dose; - Evaluate the acute, subacute and chronic adverse events following P-PRRT; - Correlate toxicity (i.e. occurence and severity of adverse events) with absorbed radiation doses to organs at risk; - Optimize the quantitative SPECT imaging-based dosimetry methods in a subset of 20 patients (sub-study funded by the Canadian Institutes of Health Research). This study also has a compassionate purpose, which is to provide access to PRRT to patients.

NCT ID: NCT02644265 Recruiting - Clinical trials for Consciousness Disorders

CONNECT-ME: Consciousness in Neurocritical Care Cohort Study Using fMRI and EEG

CONNECT-ME
Start date: April 12, 2017
Phase:
Study type: Observational [Patient Registry]

Detecting preserved consciousness in brain-injured patients by traditional clinical means requires presence of motor function. Otherwise, patients may be erroneously classified as being in a vegetative state. In order to circumvent the need for motor function, paradigms using functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) have been developed. According to a recent meta-analysis, 15% of patients with a clinical diagnosis of vegetative state can follow commands by performing mental imaginary tasks, strongly suggesting they are indeed conscious. This is of utmost importance for prognosis, treatment, and resource allocation. However, consciousness paradigms are usually employed in rehabilitation medicine. Therefore, opportunities to optimize patient outcome at an early stage may be lost. As a novel approach, the CONsciousness in NEurocritical Care cohorT study using fMRI and EEG (CONNECT-ME) will import the full range of consciousness paradigms into neurocritical care. The investigators aim to assess patients with acute brain injury for preserved consciousness by serial multimodal evaluations using active, passive and resting state fMRI- and EEG-based paradigms. A prospective longitudinal database and a biobank for genomic and metabolomic research will be established. This approach will add essential clinical information, including detection of preserved consciousness in patients previously thought of as unconscious. Due to its complexity, this project is divided into nine work packages. Eventually, the investigators will have established a clinical service for the systematic assessment of covert consciousness, as well as an interdisciplinary research group dedicated to the neuronal mechanisms by which consciousness recovers after acute brain injury.

NCT ID: NCT03075995 Recruiting - Breast Cancer Clinical Trials

To Discuss the Best Mode for Taking Lapatinib Under the Influence of the Diet

Start date: April 12, 2017
Phase: N/A
Study type: Interventional

Food can make a big difference on the bioavailability of lapatinib in breast cancer patients,and fatty food can increase the lapatinib bioavailability.By examine the steady blood drug concentration in the same individual at different treatment mode for lapatinib,emptiness or taken with fatty food,discuss the best mode of taking lapatinib with fatty food.

NCT ID: NCT03123497 Recruiting - Clinical trials for Idiopathic Thrombocytopenic Purpura

Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura (Kid's ITP Tools)

KIT
Start date: April 12, 2017
Phase:
Study type: Observational [Patient Registry]

Assessment of quality of life of patient with chronic idiopathic thrombocytopenic purpura according to the type of treatment

NCT ID: NCT03207854 Recruiting - Malignant Neoplasm Clinical Trials

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

Start date: April 12, 2017
Phase:
Study type: Observational

This research trial collects and stores blood, tissue, and bone marrow specimens from patients with cancer or blood disorders, and healthy volunteers to study the immune system in a variety of different types of experiments, as well as associated clinical data as appropriate, focused on understanding mechanisms of immunotherapy.

NCT ID: NCT03251885 Recruiting - Preterm Labor Clinical Trials

Extended-spectrum β-lactamase -Producing Enterobacteriaceae (ESBL) Vertical Transmission in Women With Preterm Labor Versus Those in Term Pregnancy

Start date: April 12, 2017
Phase:
Study type: Observational

The aims of the study are to evaluate the rate of ESBL-producing Enterobacteriaceae colonization among women in preterm labor and term labor, the incidence of maternal vertical transmission of ESBL, and the clinical significance of ESBL in preterm infants.